Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment
Objective to evaluate the efficacy and safety of candonilimab combined with anlotinib in the treatment of progressive or metastatic soft tissue sarcoma that failed previous first-line standard therapy.
Soft Tissue Sarcoma
DRUG: Candonilimab
objective response rate (ORR), The proportion of patients whose tumor volume reduced by 30% and could maintain for more than 4 weeks, that is, the sum of the proportion of complete remission (CR) and partial remission (PR), through study completion，an average of 1 year
disease control rate （DCR), The percentage of disease remission (including complete remission and partial remission, pr+cr) and stable disease (SD) in the number of evaluable cases after treatment, through study completion，an average of 1 year|Duration of Response(DOR), Remission duration refers to the time from the first CR or PR to disease progression., through study completion，an average of 1 year|time-to-response (TTR), It refers to the overall time from the time of tumor occurrence to the patient's death, through study completion，an average of 1 year|Progression-Free-Survival （PFS）, Time from randomization to disease progression, through study completion，an average of 1 year|Overall survival （OS）, The overall survival time of tumor patients, through study completion，an average of 1 year|Adverse events, The incidence and severity of adverse events (AES) and clinically significant abnormal laboratory test results., through study completion，an average of 1 year
Objective to evaluate the efficacy and safety of candonilimab combined with anlotinib in the treatment of progressive or metastatic soft tissue sarcoma that failed previous first-line standard therapy.